SCHEMBL9608313

SCHEMBL9608313

Cc1ccc(Cn2cc3c(c2Nc2ccccc2)c(=O)n(C)c(=O)n3CC2CCCN2C)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1B Q01064 3/20 0.45
PDE1A P54750 2/20 0.45
PDE1C Q14123 2/20 0.45
HTR6 P50406 2/20 0.37
ADRA1A P35348 7/20 0.37
HRH1 P35367 7/20 0.37
ADRA1B P35368 6/20 0.37
ALDH1A1 P00352 1/20 0.37
CHRNB1 P11230 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNB3 Q05901 1/20 0.36
PARG Q86W56 1/20 0.36
KAT2B Q92831 1/20 0.35
HRH3 Q9Y5N1 3/20 0.35
KCNH2 Q12809 1/20 0.35
PDE2A O00408 1/20 0.35
GABRA1 P14867 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13334361 0.91 PDE1B (0.47) PDE1BPDE1APDE1CHTR6ADRA1A
SCHEMBL13334372 0.82 PDE1B (0.46) PDE1BPDE1APDE1CHTR6ADRA1A
SCHEMBL9608346 0.82 PRKDC (0.49) ALDH1A1
SCHEMBL9608309 0.81 PDE1B (0.43) PDE1BPDE1APDE1CHTR6ADRA1A
SCHEMBL2612345 0.79 PDE1B (0.54) PDE1BPDE1APDE1CADRA1AHRH1
SCHEMBL2459282 0.76 PDE1B (0.71) PDE1BPDE1APDE1CALDH1A1CHRNB2
SCHEMBL9608316 0.74 PDE1B (0.58) PDE1BPDE1APDE1CALDH1A1CHRNB2
SCHEMBL678927 0.73 PDE1B (0.44) PDE1BPDE1APDE1CADRA1AHRH1
SCHEMBL13334384 0.73 PRKDC (0.48) PDE1B
SCHEMBL9608334 0.71 PDE1B (0.52) PDE1BPDE1APDE1CALDH1A1PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353556-A1 ORGANIC COMPOUNDS LI PENG (US) 2015-12-10 US disclosed
US-8927556-B2 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds INTRA-CELLULAR THERAPIES, INC. (US) 2015-01-06 US disclosed
US-20120136013-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES. INC. 2012-05-31 US disclosed
US-20120136013-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES. INC. 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353556-A1 ORGANIC COMPOUNDS CYP2C9, TPMT, CYP2C19 PDE1B 4863/4885PDE1A 4874/4885PDE1C 4862/4885
US-20120136013-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A4 PDE1B 4855/4885PDE1A 4874/4885PDE1C 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.